Company Filing History:
Years Active: 2023-2025
Title: Leena Ravindra Yeolekar: Innovator in Vaccine Development
Introduction
Leena Ravindra Yeolekar is a prominent inventor based in Pune, Maharashtra, India. She has made significant contributions to the field of vaccine development, particularly in creating innovative compositions for live attenuated influenza vaccines. With a total of 2 patents to her name, her work is pivotal in advancing public health.
Latest Patents
Leena's latest patents include a stabilized live attenuated influenza vaccine composition. This invention provides methods for manufacturing and obtaining a live attenuated influenza vaccine (LAIV) that can be delivered intranasally. The LAIV strains are based on cold-adapted, temperature-sensitive, and attenuated phenotypes of master donor viruses (MDVs) containing the surface glycoprotein genes of wild-type pandemic or seasonal influenza strains. Notably, the use of eggs is avoided in large-scale vaccine manufacturing, and the purification process is devoid of chromatography steps. Additionally, her other patent focuses on stable lyophilized immunogenic compositions that include live attenuated recombinant flaviviruses, particularly dengue viruses. These compositions are designed to preserve virus viability, immunogenicity, and stability while being free from preservatives, polymers, and surfactants.
Career Highlights
Leena Yeolekar is associated with the Serum Institute of India Private Limited, a leading organization in vaccine production. Her work at this esteemed institution has allowed her to contribute to groundbreaking advancements in immunology and vaccine technology.
Collaborations
Leena collaborates with notable colleagues such as Rajeev Mhalasakant Dhere and Vinit Kumar, who share her commitment to innovation in vaccine research and development.
Conclusion
Leena Ravindra Yeolekar's contributions to vaccine development exemplify her dedication to improving public health through innovative solutions. Her patents reflect her expertise and commitment to advancing medical science.